MedTrace Logo

Remission in Subjects With Crohn's Disease, Open Label Extension

NCT01070303 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2011-04-11

Study results available
· View outcomes & findings →

Summary

The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate the long-term safety of adalimumab when administered to participants with Crohn's disease.

Conditions

Interventions

BIOLOGICAL

Adalimumab 40 mg eow or ew

Adalimumab 40 mg by subcutaneous injection every other week or every week

Sponsors & Collaborators

Principal Investigators

  • Anne Camez, MD · Abbott

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01070303 on ClinicalTrials.gov